Carina Stegmayr1, Dennis Oliveira1, Nicole Niemietz1, Antje Willuweit1, Philipp Lohmann1, Norbert Galldiks1,2, N Jon Shah1,3,4, Johannes Ermert1,5, Karl-Josef Langen6,5. 1. Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, Jülich, Germany. 2. Department of Neurology, University of Cologne, Cologne, Germany. 3. Department of Neurology, RWTH University, Aachen, Germany. 4. Jülich-Aachen Research Alliance (JARA)-Section JARA-Brain, RWTH Aachen University, Aachen, Germany; and. 5. Department of Nuclear Medicine, RWTH University Hospital, Aachen, Germany. 6. Institute of Neuroscience and Medicine (INM-3, INM-4, INM-5, INM-11), Forschungszentrum Jülich, Jülich, Germany k.j.langen@fz-juelich.de.
Abstract
Restoration of the blood-brain barrier (BBB) after antiangiogenic therapy of gliomas with bevacizumab may result in a decrease in contrast enhancement on MRI despite tumor progression. This so-called pseudoresponse is difficult to differentiate from a true tumor response with conventional MRI. Initial patient studies have indicated that PET using O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) may be helpful for solving this diagnostic problem. This study was performed to investigate the effects of bevacizumab on BBB permeability and 18F-FET uptake in a human xenograft model. Methods: Human U87 glioblastoma cells were implanted into the striatum of immunodeficient RNU rats. 18F-FET PET scans and ex vivo autoradiography were performed in animals receiving a single high dose of bevacizumab (45 mg/kg 2 d before PET; n = 9) or in animals receiving 2 lower doses (10 mg/kg 9 and 2 d before PET; n = 10) to evaluate short-term and long-term effects on the BBB, respectively, and in control animals without bevacizumab treatment (n = 8). Time-activity curves, slope, and tumor-to-brain ratios of 18F-FET uptake (18-61 min after injection) were evaluated using a volume-of-interest analysis. After PET scanning, Evans blue dye (EBD) was injected into animals, and cryosections of the brains were evaluated by autoradiography, by histology, and for EBD fluorescence to assess BBB permeability. Results: Compared with the control, short-term bevacizumab therapy resulted in a trend toward BBB restoration (P = 0.055) and long-term therapy resulted in a significant decrease (P = 0.004) in BBB permeability, as assessed by EBD fluorescence. In contrast, no significant differences in tumor-to-brain ratios or slope of 18F-FET uptake were observed in PET and autoradiography (P > 0.05). Conclusion: 8F-FET uptake in glioblastomas seems to be largely independent of BBB permeability and reflects the viability of tumor tissue during antiangiogenic therapy more reliably than contrast-enhanced MRI.
Restoration of the blood-brain barrier (BBB) after antiangiogenic therapy of gliomas with bevacizumab may result in a decrease in contrast enhancement on MRI despite tumor progression. This so-called pseudoresponse is difficult to differentiate from a true tumor response with conventional MRI. Initial patient studies have indicated that PET using O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) may be helpful for solving this diagnostic problem. This study was performed to investigate the effects of bevacizumab on BBB permeability and 18F-FET uptake in a human xenograft model. Methods:Human U87 glioblastoma cells were implanted into the striatum of immunodeficient RNU rats. 18F-FET PET scans and ex vivo autoradiography were performed in animals receiving a single high dose of bevacizumab (45 mg/kg 2 d before PET; n = 9) or in animals receiving 2 lower doses (10 mg/kg 9 and 2 d before PET; n = 10) to evaluate short-term and long-term effects on the BBB, respectively, and in control animals without bevacizumab treatment (n = 8). Time-activity curves, slope, and tumor-to-brain ratios of 18F-FET uptake (18-61 min after injection) were evaluated using a volume-of-interest analysis. After PET scanning, Evans blue dye (EBD) was injected into animals, and cryosections of the brains were evaluated by autoradiography, by histology, and for EBD fluorescence to assess BBB permeability. Results: Compared with the control, short-term bevacizumab therapy resulted in a trend toward BBB restoration (P = 0.055) and long-term therapy resulted in a significant decrease (P = 0.004) in BBB permeability, as assessed by EBD fluorescence. In contrast, no significant differences in tumor-to-brain ratios or slope of 18F-FET uptake were observed in PET and autoradiography (P > 0.05). Conclusion: 8F-FET uptake in glioblastomas seems to be largely independent of BBB permeability and reflects the viability of tumor tissue during antiangiogenic therapy more reliably than contrast-enhanced MRI.
Authors: Norbert Galldiks; Veronika Dunkl; Garry Ceccon; Caroline Tscherpel; Gabriele Stoffels; Ian Law; Otto M Henriksen; Aida Muhic; Hans S Poulsen; Jan Steger; Elena K Bauer; Philipp Lohmann; Matthias Schmidt; Nadim J Shah; Gereon R Fink; Karl-Josef Langen Journal: Eur J Nucl Med Mol Imaging Date: 2018-07-07 Impact factor: 9.236
Authors: Lena Kaiser; Adrien Holzgreve; Stefanie Quach; Michael Ingrisch; Marcus Unterrainer; Franziska J Dekorsy; Simon Lindner; Viktoria Ruf; Julia Brosch-Lenz; Astrid Delker; Guido Böning; Bogdana Suchorska; Maximilian Niyazi; Christian H Wetzel; Markus J Riemenschneider; Sophia Stöcklein; Matthias Brendel; Rainer Rupprecht; Niklas Thon; Louisa von Baumgarten; Jörg-Christian Tonn; Peter Bartenstein; Sibylle Ziegler; Nathalie L Albert Journal: Cancers (Basel) Date: 2021-12-23 Impact factor: 6.639
Authors: Shuncong Wang; Yuanbo Feng; Lei Chen; Jie Yu; Chantal Van Ongeval; Guy Bormans; Yue Li; Yicheng Ni Journal: Am J Cancer Res Date: 2022-09-15 Impact factor: 5.942